Joshua Benjamin. StopekDownload PDFPatent Trials and Appeals BoardAug 29, 201913440223 - (D) (P.T.A.B. Aug. 29, 2019) Copy Citation UNITED STATES PATENT AND TRADEMARK OFFICE UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov APPLICATION NO. FILING DATE FIRST NAMED INVENTOR ATTORNEY DOCKET NO. CONFIRMATION NO. 13/440,223 04/05/2012 Joshua Benjamin Stopek H-US-02265(203-7502) 3079 50855 7590 08/29/2019 Covidien LP 60 Middletown Avenue Mailstop 54, Legal Dept. North Haven, CT 06473 EXAMINER CHAO, ELMER M ART UNIT PAPER NUMBER 3793 NOTIFICATION DATE DELIVERY MODE 08/29/2019 ELECTRONIC Please find below and/or attached an Office communication concerning this application or proceeding. The time period for reply, if any, is set in the attached communication. Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es): docket@carterdeluca.com rs.patents.two@medtronic.com PTOL-90A (Rev. 04/07) UNITED STATES PATENT AND TRADEMARK OFFICE ____________ BEFORE THE PATENT TRIAL AND APPEAL BOARD ____________ Ex parte JOSHUA BENJAMIN STOPEK ____________ Appeal 2019-001510 Application 13/440,2231 Technology Center 3700 ____________ Before ANTON W. FETTING, JOSEPH A. FISCHETTI, and MICHAEL C. ASTORINO, Administrative Patent Judges. ASTORINO, Administrative Patent Judge. DECISION ON APPEAL Pursuant to 35 U.S.C. § 134(a), the Appellant appeals from the Examiner’s decision rejecting claims 1–11, 13–19, 21, and 23. We have jurisdiction over the appeal under 35 U.S.C. § 6(b). We REVERSE. 1 “The real party in interest for the above-identified application is Covidien LP.” Appeal Br. 1. Appeal 2019-001510 Application 13/440,223 2 STATEMENT OF THE CASE Claimed Subject Matter Claims 1 and 11 are the independent claims on appeal. Claim 1, reproduced below, is illustrative of the claimed subject matter. 1. A surgical instrument for treating tissue during use of a diagnostic scanning device, the surgical instrument comprising: a housing; an end effector assembly including first and second jaw members moveable relative to one another and a plurality of fasteners; and an actuating mechanism configured to eject the plurality of fasteners from the end effector assembly; wherein at least a portion of the end effector assembly is constructed from a material that is compatible with the diagnostic scanning device and that allows a user to insert and activate the end effector assembly to thereby treat tissue at a surgical site within a patient while the surgical site is monitored during diagnostic testing, wherein the entire end effector assembly is at least one of clear, transparent, translucent, and radio-translucent to the scanning device. Rejections I. Claims 1–11 are rejected under 35 U.S.C. § 112(a) or 35 U.S.C. § 112 (pre-AIA), first paragraph, as failing to comply with the written description requirement. Appeal 2019-001510 Application 13/440,223 3 II. Claims 1, 2, 4–11, 13–16, 18, 19, and 23 are rejected under 35 U.S.C. § 103(a) as unpatentable over Zemlok,2 Saadat,3 Hooven4 or Blake,5 and McGuckin6.7 III. Claims 3 and 17 are rejected under 35 U.S.C. § 103(a) as unpatentable over Zemlok, Saadat, Hooven or Blake, McGuckin, and Chernomorsky8. IV. Claim 21 is rejected under 35 U.S.C. § 103(a) as unpatentable over Zemlok, Saadat, Hooven or Blake, McGuckin, and Aranyi9. V. Claims 1, 2, 4–11, 13–16, 18, 19, and 23 are rejected under 35 U.S.C. § 103(a) as unpatentable over To,10 Zemlok, Saadat, Hooven, and McGuckin.11 VI. Claims 3 and 17 are rejected under 35 U.S.C. § 103(a) as unpatentable over To, Zemlok, Saadat, Hooven, McGuckin, and Chernomorsky. VII. Claim 21 is rejected under 35 U.S.C. § 103(a) as unpatentable over To, Zemlok, Saadat, Hooven, McGuckin, and Aranyi. 2 Zemlok et al. (US 2009/0114701 A1, pub. May 7, 2009). 3 Saadat et al. (US 2005/0251177 A1, pub. Nov. 10, 2005). 4 Hooven (US 6,086,586, iss. July 11, 2000). 5 Blake, III (US 6,423,079 B1, iss. July 23, 2002). 6 McGuckin, Jr. (US 6,264,086 B1, iss. July 24, 2001). 7 Although the statement of the rejection fails to include claims 4 and 18, the Examiner rejects these claims under this ground of rejection. Final Act. 6, 9. 8 Chernomorsky et al. (US 2007/0135711 A1, pub. June 14, 2007). 9 Aranyi et al. (US 8,128,643 B2, iss. Mar. 6, 2012). 10 To (US 2011/0098531 A1, pub. Apr. 28, 2011). 11 Although the statement of the rejection fails to include claims 4 and 18, the Examiner rejects these claims under this ground of rejection. Final Act. 11, 13. Appeal 2019-001510 Application 13/440,223 4 Withdrawn Rejection The Examiner has withdrawn the rejection of claims 1 and 23 under 35 U.S.C. § 103(a) as unpatentable over To and Zemlok. Ans. 3. ANALYSIS Rejection I The Examiner rejects claims 1, 8, 10, and 11 as failing to comply with the written description requirement because “there is no support for the end effector including fasteners and the entire end effector (including the fasteners) being clear, transparent, translucent, or radio-translucent to the scanning device.” Final Act. 5. The Examiner’s position is that the Specification, specifically at paragraph 41,12 “fails to state that the end effector is defined as including the stapler/staples.” Id. The Appellant argues, “when the specification is read as a whole, the specification provides support for the staples or ‘fasteners’ to be part of the recited end effector assembly and ‘the entire end effector assembly is at least one of clear, transparent, translucent, and radio-translucent to the scanning device’ as recited in claim 1.” Appeal Br. 6; see id. at 5 (citing Spec. ¶¶ 25, 29, 38); Reply Br. 2–3 (citing Spec. ¶¶ 29, 37–44). The Appellant’s argument is persuasive. The Appellant points out that the Specification discloses “all” of the surgical instruments (e.g., surgical clip applier, surgical stapling device) may 12 The Examiner cites to “paragraph 43 of the publication” (Final Act. 5), which we understand as a reference to Stopek (US 2012/0316424 A1, pub. Dec. 13, 2012). Stopek’s paragraph 43 corresponds to paragraph 41 of the present application’s Specification. Appeal 2019-001510 Application 13/440,223 5 be made of a clear, translucent, and/or radio-translucent plastic. See Appeal Br. 5 (citing Spec. ¶ 29); see also Spec. ¶¶ 7 (“The end effector may be clear, transparent, translucent or radio-translucent to the scanning device.”), 34, 39, 43, 47. And, the Appellant points out that the “[S]pecification discloses that staples are part of the end effector assembly.” Reply Br. 2–3 (citing Spec. ¶¶ 37–44). For example, the Appellant points out that from paragraph 38, “it is clear that the staples are part of the cartridge 204 which is part of jaw 203.” Appeal Br. 5–6 (citing Spec. ¶ 38). Indeed, paragraph 38 describes: In operation, surgical stapling device 200 is fired similarly to and in accordance with other known surgical stapling devices. That is, firing knob 207 is actuated, i.e. advanced distally, to eject the staples from cartridge 204 into contact with anvil member 208. In some embodiments, all or a portion of surgical stapling device 200, and/or at least a portion of jaws 203, 205, is constructed with non-ferrous metals to avoid any adverse effects on imaging during MRI scanning. Other suitable materials, for example, copolymers, plastics and/or carbon fiber may also be utilized. One of ordinary skill in the art would understand that this paragraph discloses staples as part of a staple cartridge. Elsewhere in the Specification staple cartridges are identified as part of an end effector assembly. See Spec. ¶¶ 35, 37. The Examiner disagrees with the Appellant’s argument because “it pieces together bits and pieces of the concept in question from disparate portions of the specification, then requires a stretch of the imagination to conclude that the concept as a whole has support.” Ans. 4. The Examiner’s position is that paragraphs 25, 29, and 38 of the Specification fail to Appeal 2019-001510 Application 13/440,223 6 “disclose that the staples are considered as part of the end effector assembly, and furthermore do not provide support for staples (fasteners) being [clear, transparent, translucent, and radio-translucent].” Id. In this case, it appears that the Examiner’s rejection is based on the lack of verbatim support in the Specification. However, the claimed invention need not be recited in haec verba in the original specification to satisfy the written description requirement. Ariad Pharms., Inc. v. Eli Lilly & Co., 598 F.3d 1336, 1352 (Fed. Cir. 2010) (en banc). The fundamental factual inquiry is whether the specification conveys with reasonable clarity to those skilled in the art that, as of the filing date sought, applicant was in possession of the invention as now claimed. See, e.g., Vas-Cath Inc. v. Mahurkar, 935 F.2d 1555, 1563–64 (Fed. Cir. 1991). We determine that the Examiner’s position is not adequately supported. Further, the Examiner fails to adequately explain another reason –– on the record –– why the subject matter of claims 1, 8, 10, and 11 fails to comply with the written description requirement. Thus, we do not sustain the Examiner’s rejection of claims 1, 8, 10, and 11 as failing to comply with the written description requirement (Rejection I). Rejections II–IV Independent claim 1 calls for a surgical instrument for treating tissue during use of a diagnostic scanning device including, among other things, an end effector assembly having a plurality of fasteners and recites that “the entire end effector assembly is at least one of clear, transparent, translucent, and radio-translucent to the scanning device.” Appeal Br., Claims App. Appeal 2019-001510 Application 13/440,223 7 (emphasis added). Independent claim 11 calls for a method of treating tissue where a similar surgical instrument is provided. See id. Turning to the rejection of independent claims 1 and 11, the Examiner does not find that Zemlok, Saadat, Hooven or Blake, and McGuckin, by themselves, teach an end effector assembly where the entirety of an end effector assembly is at least one of clear, transparent, translucent, and radio- translucent to a particular diagnostic scanning device, as required by the claims. More specifically, the rejection does not rely on Saadat or McGuckin to teach an end effector that is clear, transparent, translucent, or radio-translucent to a scanning device. See Final Act. 7–9. In this case, the Examiner finds that Zemlok and Hooven or Blake teach different portions of an end effector assembly that are transparent, but does not find that these references teach an entire end effector, including a plurality of fasteners, as at least one of clear, transparent, translucent, and radio-translucent to the scanning device as claimed. See id. at 7 (citing Zemlok ¶¶ 6, 7, 10, 37; Hooven, col. 2, ll. 34–43, col. 4, ll. 46–53, claim 21; Blake, col. 4, ll. 32– 43). Nonetheless, the Examiner concludes that “it would have been obvious to one of ordinary skill in the art . . . to have the end effector assembly be entirely transparent to the scanning device” for various reasons, including “in order to permit the operator to view the extent of tissue fastening and to verify the tissue is in place before the fastening procedure.” Final Act. 7–8; see Ans. 5–8. The Appellant argues that the combined teachings of Zemlok, Saadat, Hooven or Blake, and McGuckin fail to teach or suggest an “entire end effector assembly [that] is at least one of clear, transparent, translucent, and radio-translucent to the scanning device,” as claimed. Appeal Br. 7–8 Appeal 2019-001510 Application 13/440,223 8 (emphasis omitted); Reply Br. 5. Most notably, the Appellant asserts that Zemlok, Hooven, and Blake only teach portions of an end effector assembly, rather than the entire assembly, as transparent. See Appeal Br. 10–13; Reply Br. 5. The Appellant’s argument is persuasive. In this case, the Examiner’s rejection does not identify the individual components of an end effector assembly, including a plurality of fasteners, and suggest that each of the individual components of the end effector assembly are at least one of clear, transparent, translucent, or radio- translucent to a scanning device. For example, the Examiner does not find that any one of Zemlok, Hooven, or Blake, teach a fastener (e.g. staples) of an end effector assembly that are either clear, transparent, translucent, or radio-translucent to a scanning device. Therefore, on record before us, the Examiner’s conclusion of obviousness fails to articulate reasoning with rational underpinning because the support for the reasoning only demonstrates that the cited prior art teaches that some, but not all, of portions of an end effector assembly may be at least one of clear, transparent, translucent, and radio-translucent to a scanning device. See Appeal Br. 13–14. Thus, we do not sustain the Examiner’s rejection of claims 1, 2, 5–11, 13–16, 19, and 23 as unpatentable over Zemlok, Saadat, Hooven or Blake, and McGuckin (Rejection II). The remaining rejections based on Zemlok, Saadat, Hooven or Blake, and McGuckin in combination with Chernomorsky or Aranyi include the same reasoning that lacks rational underpinning as discussed above. Each of these rejections is not cured by additional findings and/or reasoning associated therewith. Thus, we do not sustain the rejections of: claims 3 and 17 as unpatentable over on Zemlok, Saadat, Hooven or Blake, Appeal 2019-001510 Application 13/440,223 9 McGuckin, and Chernomorsky (Rejection III); and claim 21 as unpatentable over on Zemlok, Saadat, Hooven or Blake, McGuckin, and Aranyi (Rejection IV). Rejections V–VII The Examiner’s rejection of independent claims 1 and 11 based on the combined teachings To, Zemlok, Saadat, Hooven, and McGuckin includes similar reasoning lacking rational underpinning as discussed above with regards to Rejection II. See Final Act. 11–13. Therefore, for similar reasons as discussed above we do not sustain the rejections of: claims 1, 2, 5–11, 13– 16, 19, and 23 as unpatentable over To, Zemlok, Saadat, Hooven, and McGuckin (Rejection V). The remaining rejections based on To, Zemlok, Saadat, Hooven, and McGuckin in combination with Chernomorsky or Aranyi include the same reasoning that lacks rational underpinning as discussed above. Each of these rejections is not cured by additional findings and/or reasoning associated therewith. Thus, we do not sustain the rejections of: claims 3 and 17 as unpatentable over on To, Zemlok, Saadat, Hooven, McGuckin, and Chernomorsky (Rejection VI); and claim 21 as unpatentable over on To, Zemlok, Saadat, Hooven, McGuckin, and Aranyi (Rejection VII). DECISION We REVERSE the Examiner’s decision rejecting claims 1–11, 13–19, 21, and 23. REVERSED Copy with citationCopy as parenthetical citation